Instrument Inactif

Autres langues Neurometrix Inc Nasdaq

Actions

US6412555004

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

19/04	Neurometrix, Inc. nomme Joshua S. Horowitz comme administrateur de classe III au sein du conseil d'administration	CI
14/03	NeuroMetrix, Inc. annonce la publication d'une étude démontrant que le DPNCheck diagnostique avec précision la neuropathie diabétique périphérique	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Sector Update: Health Care Stocks Advance Late Afternoon	19/04
Sector Update: Health Care Stocks Rise Friday Afternoon	19/04
NeuroMetrix Says Joshua Horowitz Joining Board, Terminates At-the-Market Equity Facility	19/04
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value	19/04
Neurometrix, Inc. Appoints Joshua S. Horowitz as a Class III director on the Board	19/04
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)	20/03
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy	14/03
NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy	14/03
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia	13/03
Ephraim Fields Discloses his Views on NeuroMetrix	27/02
RS Fund Discloses its Views on NeuroMetrix	26/02
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights	22/02
NeuroMetrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
NeuroMetrix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call	15/02
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value	13/02
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value	13/02
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024	08/01
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)	12/12
Neurometrix, Inc. Reports Encouraging Results from Pilot Clinical Trial of Quell®? in Post-Acute Covid-19 Syndrome (Long Covid)	12/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Neurometrix Inc Nasdaq

Actions

US6412555004

Autres langues

Filtres